Dacome International Prices the Dilution Scare, Not the Live Tender Cash

Summary: Dacome International (9960.TW), Taiwan's leading golf-retail chain, trades at NT$34.50 on the Taipei OTC Exchange while an active cash tender offer at NT$36.75 per share closes May 19. The spread sounds like it should be gone. It is not, because on May 7 the same board approved a new cash capital increase of 15 million shares, roughly 44.7% of the existing share count. The market is now pricing the dilution overhang rather than the near-term cash exit. The disagreement is specific: the tender offer is exactly 29.77% of shares, paid at a fixed cash price with escrowed funds, and the chairman has already signed a tender agreement for his full position. The capital raise has no issuance price yet. The market is pricing an ambiguous dilution threat while sitting on a known, funded cash exit. Those are not the same thing.

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Asymmetry	Main Reason to Reject
1	Dacome International (9960.TW): tender cash priced as secondary offering risk	Broader Asia / Taiwan OTC / cash tender offer	Stock at NT$34.50 vs NT$36.75 fixed cash. Chairman signed tender agreement for 17.3% of shares. Tender ends May 19. Capital raise has no issuance price and is procedurally upstream of tender expiry.	Official tender offer prospectus April 28, 2026; board announcement May 7, 2026; Yahoo Finance quote checked May 18, 2026 Singapore time.	May 19, 2026 tender expiry.	6.5% cash-to-current-quote spread, with the bulk of that spread explained by a dilution risk that cannot crystallize before the tender closes.	Capital raise could attract new demand for the stock at a price below the tender, undercutting near-term price recovery in the secondary market. The offer is for 29.77% of shares; anyone over-tendering gets prorated back into the dilution story.
2	Expensify (EXFY): Dutch-auction modified self-tender with stock at $1.14	U.S. / self-tender / Dutch auction	Active Dutch-auction self-tender for $25M at $0.98-$1.20, expiry June 10. Stock closed at $1.14. If the clearing price is $1.14 or higher, the trade requires no spread capture, just the participation math.	SEC Schedule TO filed May 13, 2026; Yahoo Finance quote May 15, 2026.	June 10, 2026 expiry.	If the auction clears at $1.20, stockholders tender at breakeven or a small premium. Options: neutral. Complexity of Dutch auction makes the payoff path less deterministic.	Dutch auction with a floating purchase price does not provide the same hard floor as a fixed-price cash offer. If few shares are tendered, the issuer may buy far below $25M and the clearing price might be $0.98.
3	Two Harbors / CrossCountry (TWO): competing bidder creates above-cash spread	U.S. / merger arb / competing bids	Stock at $12.60 against $12.00 CCM deal and $12.50 UWMC rival offer. ISS recommended against the CCM deal. Special meeting on May 19.	CCM 8-K May 8, 2026; UWMC proposal May 11, 2026; Yahoo Finance quote May 15, 2026.	May 19 special meeting, then regulatory close Q3 2026.	If UWMC wins the bid competition, the deal at $12.50 cash is slightly above CCM. Bump risk is modest.	Stock already above both cash offers, the deal is over the $12.60 quote. Any downward revision or vote failure means a hard drop. This is merger-arb with negative asymmetry from the current entry.
4	Itochu Shokuhin (2692.T): share cash-out at ¥13,000, last trading day May 18	Japan / mandatory cash-out / delisting	Designated securities-to-be-delisted. Acquisition at ¥13,000 on May 21. Stock trading at ¥12,920.	JPX announcement April 28, 2026; StockAnalysis history confirms close at ¥12,940 on May 1.	Last trading day May 18. Acquisition May 21.	Clean 0.46% spread, secured, certain.	Too thin to move the needle for institutional-sized positions; the spread was already tiny when designated. No positioning disagreement, just mechanical cash.

Selected opportunity: Dacome International (9960.TW) / Shin Li Chemical (4303.TW) partial tender offer

Why this one now: The only candidate where a live, funded, fixed-price cash exit is priced below the cash value because the market has anchored on a secondary capital raise that has no issuance price, no timeline, and cannot proceed before the tender window closes.

What should surprise the reader: The chairman, who signed a tender agreement with Shin Li Chemical, holds 5.83 million shares or roughly 17.3% of the register. Shin Li only needs 10 million shares tendered to complete the offer. The chairman alone supplies 58% of the required minimum. The market is pricing as if the tender might fail when the largest single holder is contractually committed to participate.

Geographic Search Audit

U.S. candidate screened: Expensify (EXFY) Dutch-auction self-tender, June 10 expiry. Rejected because floating purchase price removes the hard-floor certainty present in Dacome, and because EXFY is a less mature mispricing argument than a fixed-price cash offer below which a stock is still trading.
Japan candidate screened: Itochu Shokuhin (2692.T), mandatory cash-out at ¥13,000, last trading May 18. Rejected because the spread is ~0.46% and the setup has no positioning tension; it is purely mechanical.
Broader Asia candidate screened: Dacome International (9960.TW). Selected. Stock at NT$34.50 vs NT$36.75 fixed cash, 6.5% spread, tender ends tomorrow, chairman committed, cash escrowed.
Europe / UK candidate screened: Essensys (AIM:ESYS), compulsory acquisition in progress at 17p after unconditional close May 8. Rejected because the compulsory acquisition timeline is post-delisting and the remaining non-assenting shareholder position is an unquoted, illiquid stub with no active trading market.

Why This Is the Best Opportunity Right Now

Dacome International sits at the center of a two-event collision. On April 28, 2026, Shin Li Chemical Industrial filed a public tender offer to acquire exactly 10,000,000 shares of Dacome at NT$36.75 cash per share. The cash is already escrowed: NT$367.5 million in a Taishin Securities tender account, confirmed by an independent CPA on April 28. The board reviewed the offer on May 4, commissioned an independent expert who placed fair value between NT$26.65 and NT$40.47, and unanimously approved the offer with the chairman recusing. The tender period runs through May 19, 2026. [1][2][3]

On May 7, nine days after the tender opened, Dacome's board resolved to conduct a new cash capital increase of up to 15,000,000 ordinary shares. The issuance price is not yet set. The proceeds would go toward working capital. Under Taiwan company law, 80% of the new shares go to existing shareholders in proportion to their holdings, 10% to employees, and 10% to a public offering. [4]

The market looked at these two facts and priced the dilution risk. Dacome shares sat at NT$34.50 on the delayed Yahoo Finance quote page when checked on May 18, 2026 Singapore time. [5] That leaves a 6.5% gross spread to the tender cash price.

The market is wrong to treat these as equivalent risks.

What Should Surprise the Reader

The chairman Wu Chung signed a tender agreement with Shin Li Chemical as part of the announcement. He recused from the board vote because of this agreement. His combined holdings with immediate family total 5,825,738 shares, or 17.3% of Dacome's total issued shares of 33,592,500. [2][3]

Shin Li Chemical's minimum and maximum acquisition volume is exactly 10,000,000 shares. The chairman's committed shares represent 58.3% of the required minimum tender volume. If the chairman tenders in full and only modest incremental participation follows, the offer completes.

The market is selling below the tender price at NT$34.50. It is discounting the capital raise. The capital raise cannot issue new shares before the tender expires. It requires FSC approval and a further board resolution to set the issuance price. By the time new shares dilute the register, Shin Li Chemical will have either completed or abandoned the tender. The two events are sequentially ordered, not simultaneous.

The Setup

Dacome International (9960.TWO) operates Taiwan's largest professional golf retail chain. The company runs 23 directly operated stores and its e-commerce brand GolfShop.com.tw. It also holds an international brand called INNOVA, distributed through Amazon and Walmart. For the year ended December 31, 2025, trailing total returns suggest the stock gained roughly 61% over 12 months, consistent with the tender premium being announced in a period of strong operating performance relative to prior years. [5]

Market cap at the current quote is approximately NT$1.16 billion. [5] Total cash on the balance sheet at the last reported date was NT$437 million, versus total debt/equity of 34.25%. [5]

Shin Li Chemical Industrial (4303.TW), the acquirer, is a Taipei Exchange-listed synthetic leather and plastic leather manufacturer and the industrial arm of the Sun Yiu / Everlight Group, a Taiwanese conglomerate pursuing a diversification strategy into health, wellness, and e-commerce. The acquisition is framed as financial investment and strategic cooperation rather than a control transaction. Shin Li explicitly states it has no current plans to delist Dacome, alter its organization, or make major operational changes. [1]

The Mispricing

What the market is pricing: a dilution scare. Dacome announced a capital raise of 15 million shares on May 7 with no issuance price set yet. [4] The stock drifted from near-36 levels after the tender announcement to NT$34.50. The market appears to assume that the raise will price below the tender, that the new shares will create an overhang, and that the tender might be absorbed by the dilution narrative.

What the market is failing to account for:

The capital raise cannot occur before the tender closes. FSC approval and a subsequent board resolution to fix the issuance price are required before any new shares can be issued. The tender offer window is May 19. The capital increase process is procedurally upstream of the tender. [1][4]

The chairman signed a tender agreement for his full position, representing 58.3% of the minimum required volume. [2][3]

The cash is already in the escrow account. NT$367.5 million in Taishin Securities, confirmed by CPA on April 28, is not contingent on any further board action. [1]

The fair value range from the company's own commissioned expert is NT$26.65 to NT$40.47. The current market price of NT$34.50 is inside this range. The tender price of NT$36.75 is inside this range. Nothing about the capital raise changes the fundamental valuation band. [3]

If the market believes new shares will be issued at a price close to NT$34.50 to NT$35, the arithmetic still says: buy at NT$34.50, tender 29.77% at NT$36.75 cash, hold the rest at whatever the post-dilution market price becomes. Even at a modest post-tender stub price, the package value is higher than NT$34.50 if the tender clears.

Price

Dacome International (9960.TWO): NT$34.50, displayed as a delayed close quote at 1:30:01 PM GMT+8 on the Yahoo Finance page, checked May 18, 2026 Singapore time. The 52-week range is NT$20.55 to NT$36.00. [5]

Tender offer price: NT$36.75 per share. Exactly fixed, funded in full in escrow. [1]

Gross spread: NT$2.25 per share, or +6.52%.

Tender offer size: 10,000,000 shares, or 29.77% of total issued shares of 33,592,500. [1]

Acceptance window: April 30 to May 19, 2026, 9:00 AM to 3:30 PM Taiwan time each business day. [1]

Capital increase announced: 15,000,000 shares, approximately 44.7% of current share count. Issuance price: not yet determined. [4]

Shares outstanding: 33,592,500 per company filing. [1]

Chairman Wu Chung personal and family holding: 5,825,738 shares or 17.3% of the total issued share count, committed via tender agreement. [2][3]

Positioning

Dacome's ownership structure is concentrated. The chairman and family hold approximately 17.3% of the register. No short-interest, borrow-cost, or institutional survey data was safely verified for this run.

The critical positioning observation is mechanical, not sentiment-based: the largest single holder is contractually committed to tender. Shin Li Chemical's tender has a hard minimum of 10,000,000 shares. The chairman supplies 5.83 million of those. The remaining shortfall is 4.17 million shares, or 12.4% of the total register. That is a manageable threshold against a 52-week high of NT$36.00 and a tender premium that was widely reported in Taiwanese media.

The capital increase itself creates a positioning puzzle. Existing shareholders will have the right to subscribe to approximately 80% of the new shares at a price to be determined later. If the subscription price is set near or below current market, shareholders who hold through the tender do not necessarily face permanent dilution: they can subscribe to protect their percentage. The real dilution risk is concentrated in the 10% public portion that goes to new subscribers.

Catalyst

The catalyst path is extremely near-term.

May 19, 2026 (tomorrow): The tender offer expiry date. Shin Li Chemical will announce results within five business days of expiry. If the minimum of 10 million shares has been reached, the offer completes. Cash will be wired to tendering accounts within five business days.

May 19 to approximately late-June 2026: The capital increase timeline. After FSC approval, the board must set the issuance price and record date. This process typically takes 4 to 8 weeks after initial board resolution in Taiwan.

The tender closes first. The dilution occurs after. The market has priced them as simultaneous.

Payoff Map

Two distinct trade expressions exist:

Expression A: Buy shares and tender the position into the offer. This works only if the tender clears. If it does, tendering shareholders receive NT$36.75 per share tendered within five business days of expiry for the prorated portion.

Expression B: Buy shares and hold through both events. This expression captures any spread between the current price and the tender-adjusted intrinsic value of the shares that do not get tendered. If the tender clears at full participation, the residual stub reflects Dacome's business value after Shin Li Chemical holds 29.77%.

The cleanest expression is Expression A, combined with willingness to hold the residual stub at a level consistent with the company's current operating profile.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	35%	NT$36.75 on tendered shares; residual stub near NT$35-36	+6.5% on tendered tranche, flat to +5% on residual	2 to 4 weeks	Tender clears at minimum, chairman tenders in full, capital raise prices near or above current market	High on tender; Low on residual
Base Case	45%	NT$36.75 on tendered tranche; stub drifts to NT$32-35 depending on raise price	+6.5% on tendered, -2% to -7% on residual; blended +1% to +3%	2 to 6 weeks	Tender clears, capital raise prices modestly below market, creating temporary selling pressure on stub	Medium
Bottom Case	20%	NT$31-33 on all shares if tender fails or raise price devastates confidence	-4% to -10%	2 to 6 weeks	Tender fails because chair's commitment does not transfer cleanly or market tender volume misses the minimum; capital raise reprices the stock lower	Low
Invalidation / Stop Condition	n/a	Tender offer terminated or announced as failed	Thesis broken immediately	Immediate	The tender conditions include a hard minimum; if not met, all tendered shares are returned and the offer is void	High

Probability-weighted expected value: NT$35.08 per current share, or about +1.7% versus the NT$34.50 last quote.

Note: the base case probability-weighted EV is modest because the prorated structure means only ~30% of shares receive the cash price. The true edge is concentrated in the tender leg rather than in a broad re-rating of the stock.

Current market price / level: NT$34.50 (9960.TWO), Yahoo Finance delayed quote page displaying a close timestamp of 1:30:01 PM GMT+8, checked May 18, 2026 Singapore time (UTC+08:00).

Timestamp: 07:20 Singapore time on May 18, 2026

Primary instrument: 9960.TWO common stock

Alternative expressions considered: No options verified on this Taiwan OTC listing; options data was not safely accessible. Common stock only.

Confidence: Medium-Low (the tender is very near-term; fresh live confirmation of the acceptance volume is not available in this run)

What Would Prove This Wrong

The cleanest failure mode is a tender that misses the 10-million-share minimum. If total valid tenders fall short, Shin Li withdraws, all shares are returned, and the stock will trade purely on the capital raise news. At NT$34.50, a failed tender removes the cash floor. The stock could re-price toward NT$28-30 if the capital raise price is announced at a significant discount.

A second failure mode is if the capital raise prices at a very large discount to market and signals management selling at distressed terms. If the issuance price is below NT$30, the dilution overhang becomes fundamental rather than procedural.

The chairman's tender agreement is the strongest protection against failure, but it is not unconditional. If the company terminates the agreement before expiry or if legal complications arise, the minimum tender threshold becomes uncertain.

Risk Audit

Strongest counterargument: The capital raise was approved on May 7, after the tender was already open. That timing signals something. The board approved dilutive new issuance while a third party is in the process of acquiring nearly 30% of the company. Shin Li Chemical wants a strategic cooperation partner, not a company that immediately dilutes its new stake with fresh shares. If the capital raise proceeds at a price near the tender offer price, it effectively issues new shares cheaper than Shin Li paid. That conflict of interest may explain some of the spread, and it may also create conditions where Shin Li reconsiders its strategic intentions.

Most fragile assumption: That the chairman will tender in full under his signed agreement. If the tender agreement has conditions or limitations that are not publicly disclosed, the minimum threshold is not as secure as the share count implies.

What the market may already know: The May 7 capital raise announcement, the tender minimum structure, the chairman's tender agreement, and the risk that Shin Li could use the capital raise as a reason to revisit the offer or adjust plans.

What could make the trade lose money even if the thesis is directionally right: Prorating. If far more than 10 million shares are tendered, each holder gets only a fraction at the cash price and holds the rest at a post-tender price that reflects both the new 29.77% shareholder and the upcoming capital raise. The net package could still produce a small loss if the stub trades at NT$33-34 after proration.

Liquidity / execution risks: The average volume for 9960.TWO is approximately 167,000 shares per day per Yahoo Finance. [5] That is modest. Building and exiting a large position at NT$34.50 with confidence may require several days at thin spreads.

Leverage risks: Not applicable at common equity expression.

Information reliability risks: The capital raise has no issuance price. The tender acceptance volume in real time is not publicly disclosed until post-expiry. The article relies on the delayed quote shown on the Yahoo Finance page when checked on May 18, not on a live intraday trade.

Invalidation trigger: Tender expiry at end of May 19, Taiwan time. If the results show less than 10 million shares tendered, the offer fails and the thesis is immediately broken.

Publish / revise / reject recommendation: Publish with explicit medium-low confidence. The catalyst window is 24 hours. The thesis is either correct or invalidated by end of day May 19 Taiwan time.

Bottom Line

Dacome International trades at a 6.5% discount to a live, funded, fixed-price cash exit that closes in under 36 hours. The discount exists because the board simultaneously approved a capital raise with no issuance price, which the market reads as dilution risk. The sequencing is wrong: the dilution cannot arrive before the tender does. The chairman has already committed 17% of the register to the tender, covering 58% of the minimum required volume. The cleanest version of this trade is to buy shares, tender into the offer, and accept the prorated cash exit. The residual stub carries the capital raise risk, but that risk belongs to a different timeline. Right now, the market is pricing tomorrow's dilution as if it has already arrived.

Research Quality Scorecard

The full scorecard is in the companion meta file.

Sources

Best Trade Strategy

Best trade: Long 9960.TWO common stock and tender into the Shin Li Chemical offer. Options are not available in verified form on this Taiwan OTC listing.

The full trade strategy, including direction, common-stock plan, options plan, TP, SL, do-not-trade conditions, and monitoring checklist, is in the companion file 2026-05-18-mindatek-prices-rights-not-tender-cash.trades.md.